This site is intended only for healthcare professionals resident in India

Search

Menu

Close

Sign InLog Out
Our medicinesTherapy areasExplore ContentExplore contentMaterialsVideosLet's connectLet's ConnectPfizer medical information
AboutDosing & AdministrationDosing & AdministrationDosing in RADosing in PsADosing in UCPractical Considerations

Menu

Close

Efficacy & SafetyClinical Efficacy RARapid Data (ACR20)Head-to-Head Noninferiority Data (ACR50)Biologics DataClinical Efficacy PsAACR20 DataPASI75 DataEnthesitis and Dactylitis DataClinical Efficacy UC8-week EfficacyOnset of Action Data52-week EfficacyOCTAVE Study DesignSafety and TolerabilitySafety in RASafety in PsASafety in UCResources & SupportResources & SupportMaterialsVideosSummary of Prescribing Information

Reduction In Enthesitis And Dactylitis Symptoms in Patients with PsA

Patients with PsA experienced improvements in symptoms of enthesitis and dactylitis1

   

Patients receiving XELJANZ® (tofacitinib citrate) had a numerically greater mean change from baseline in the LEI score versus those receiving placebo at Month 3.1,*

OPAL Broaden in csDMARD-IR–treated Patients1​​​​​​​

   

The OPAL Broaden study was not designed to provide head-to-head comparative efficacy data versus Adalimumab and should not be interpreted as evidence of superiority or noninferiority.1

   

Example

   

Adapted from Mease P, et al. 2017.

*Patients with a baseline LEI score of 0 were excluded from the analyses.

  • In csDMARD-IR patients with enthesitis, 33.3% (25/75) had complete resolution (LEI=0) at Month 3 with XELJANZ® (tofacitinib citrate) versus 21.5% (14/65) with placebo. At Month 3, 47.4% (36/76) of patients receiving Adalimumab 40 mg SC Q2W + csDMARD had complete resolution of enthesitis1
     

  • Statistical significance for XELJANZ® (tofacitinib citrate) was not achieved under the step-down procedure1

Patients receiving XELJANZ® (tofacitinib citrate) had a numerically greater mean change from baseline in the LEI score versus those receiving placebo at Month 3.1,*  OPAL Beyond in TNFi-IR patients2

  

Adapted from Gladman D, et al. 2017.

  

*Patients with a baseline LEI score of 0 were excluded from the analyses.

  • Due to a lack of significance higher in the prespecified hierarchical testing sequence, the change from baseline in LEI at Month 3 with XELJANZ® (tofacitinib citrate) 5 mg BID + csDMARD versus placebo + csDMARD was not tested for statistical significance controlling for type I error2,4

Patients receiving XELJANZ® (tofacitinib citrate) had a numerically greater mean change from baseline in DSS versus those receiving placebo at Month 31,*

  

OPAL Broaden in csDMARD-IR–treated Patients1

  

The OPAL Broaden study was not designed to provide head-to-head comparative efficacy data versus Adalimumab and should not be interpreted as evidence of superiority or noninferiority.1

  


Adapted from Gladman D, et al. 2017.

*Patients with a baseline DSS of 0 were excluded from the analyses.

  • In csDMARD-IR patients with dactylitis, 34.4% (21/61) had complete resolution (DSS=0) at Month 3 with XELJANZ® (tofacitinib citrate) versus 32.8% (19/58) with placebo. At Month 3, 46.6% (27/58) of patients receiving Adalimumab 40 mg SC Q2W + csDMARD had complete resolution of dactylitis
     

  • Due to a lack of significance higher in the prespecified hierarchical testing sequence, the change from baseline in DSS at Month 3 with XELJANZ® (tofacitinib citrate) 5 mg BID + csDMARD versus placebo + csDMARD was not tested for statistical significance controlling for type I error2,4

Patients receiving XELJANZ® (tofacitinib citrate) had a numerically greater mean change from baseline in DSS versus those receiving placebo at Month 31,* 

   

OPAL Beyond in TNFi-IR–treated Patients2

   

  

Adapted from Gladman D, et al. 2017, Data on file. Pfizer Inc.

  

*Patients with baseline DSS of 0 were excluded from the analyses.

  • Due to a lack of significance higher in the prespecified hierarchical testing sequence, the change from baseline in DSS at Month 3 with XELJANZ® (tofacitinib citrate) 5 mg BID + csDMARD versus placebo + csDMARD was not tested for statistical significance controlling for type I error2,4

OPAL Broaden study design (the PsA-I study)

A 12-month, randomised, multicentre, double-blind trial in which 422 patients with PsA who had an inadequate response to at least 1 csDMARD and were TNFi-naïve received either XELJANZ® (tofacitinib citrate) 5 mg BID, XELJANZ® (tofacitinib citrate) 10 mg BID, Adalimumab 40 mg SC Q2W or placebo. At Month 3, all patients randomised to the placebo treatment were advanced in a blinded fashion to either XELJANZ® (tofacitinib citrate) 5 mg BID or XELJANZ® (tofacitinib citrate) 70 mg BID. Primary end points were ACR20 response and the change in HAQ-DI at Month 3.1

OPAL Broaden study design (the PsA-II study)

A randomised, 6-month, double-blind trial in which 394 patients with PsA who had an inadequate response to at least 1 TNFi received either XELJANZ® (tofacitinib citrate) 5 mg BID, XELJANZ® (tofacitinib citrate) 10 mg BID, or placebo. At Month 3, all patients randomised to placebo were advanced in a blinded fashion to either XELJANZ® (tofacitinib citrate) 5 mg BID or XELJANZ® (tofacitinib citrate) 10 mg BID. The primary end points were ACR20 response rate and the change in HAQ-DI at Month 3.2

  

XELJANZ® (tofacitinib citrate) 5 mg BID is the only approved dosage for the treatment of PsA, and it should not be exceeded. The dosage of 10 mg BID is not licensed for the treatment of PsA.

  

Explore more

Learn about the safety profile of XELJANZ® (tofacitinib citrate) in PsA

   

Learn moreLoading

  

  

ACR, American College of Rheumatology; BID, twice daily; csDMARD, conventional synthetic disease-modifying antirheumatic drug; DSS, dactylitis severity score; HAQ-DI, Health Assessment Questionnaire-Disability Index; IR, inadequate response; LEI, life events inventory; OPAL, older persons’ assessment and liaison team; PsA, psoriatic arthritis; Q2W, every 2 weeks; SC, subcutaneously; TNFi, tumour necrosis factor inhibitor.

  

References:

Mease P, Hall S, FitzGerald O, et al. Tofacitinib or adalimumab versus placebo for psoriatic arthritis. N Engl J Med. 2017;377(16):1537-1550.Gladman D, Rigby W, Azevedo VF, et al. Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors. N Engl J Med. 2017;377(16):1526-1536.Data on file. Pfizer Inc., New York, NY.Mease P, Hall S, FitzGerald O, et al. Tofacitinib or adalimumab versus placebo for psoriatic arthritis (Supplementary Appendix). N Engl J Med. 2017;377(16):1537-1550.

  

Please click the Prescribing Information link to view the safety and adverse events information of Xeljanz®.
For the use only of Registered Medical Practitioners or a Hospital or a Laboratory.


PP-XEL-IND-0843 22/07/22

Clinical Efficacy in PsA

About

XELJANZ® (tofacitinib citrate) is a small molecule that selectively targets the JAK pathway

Learn more

Dosing & Administration

   

Helps protect against RA, PsA and UC

Learn more

Resources & Support

Review the upcoming events

Learn more
PfizerPro AccountPfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign in or RegisterSign inRegisterAccountSign Out
 
These pages are not intended for patients or for members of the general public. The web pages contain promotional content. For the use only of Registered Medical Practitioners or a Hospital or a Laboratory. Full prescribing information available on request. For more details on, Who is a Registered Medical Practitioner, please visit "https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf", Page No. 39, Rule 2 part (ee), last accessed on 26th April2021.
​​​​​​​
Address: The Capital,  A Wing, 1802, 18th Floor, Plot No. C-70, ‘G’ Block, Bandra Kurla Complex, Bandra East, Mumbai – 400051, India.
 
PP-XEL-IND-0843

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

Heading

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

ButtonButton

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Hac habitasse platea dictumst quisque sagittis purus sit amet volutpat. Lectus magna fringilla urna porttitor rhoncus. Venenatis urna cursus eget nunc scelerisque viverra. Id donec ultrices tincidunt arcu non sodales.

Sagittis aliquam malesuada bibendum arcu vitae elementum curabitur. Pellentesque elit ullamcorper dignissim cras tincidunt. Orci ac auctor augue mauris augue neque. Dui vivamus arcu felis bibendum ut tristique et egestas quis. Sed vulputate mi sit amet mauris commodo.

Nunc eget lorem dolor sed viverra ipsum. Sed ullamcorper morbi tincidunt ornare.

 
Copyright © 2022 Pfizer Limited, India. All rights reserved. Applicable for Pfizer Products, Product Microsites and Therapy Areas section of the website:
  • All content published herein is intended and strictly only for informational, educational, academic and/or research purposes and shall not be utilized to diagnose or treat a health problem or disease without referring to the full prescribing information for list of approved indications as contained in the product package insert
  • ​​​​​​​While due care and caution has been taken to ensure that the content herein is free from mistakes or omissions, Pfizer makes no claims, promises or guarantees about the accuracy, completeness or adequacy of the information herein
 
For the use of Registered Medical Practitioners only*

These pages are not intended for patients or for members of the general public. The web pages contain promotional content.


If you select 'No', you will be redirected to Pfizer.co.in

For more details on, Who is a Registered Medical Practitioner*, please visit https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf , Page No. 39, Rule 2 part (ee), last accessed on 13th September 2019.
​​​​​​​Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.


PP-UNP-IND-0012 July 2022
Yes No
You are now leaving PfizerPro website
​​​​​​​ ​
​​​​​You are now leaving Pfizer Pro website and will be redirected to another website. Note that you will be governed by the Terms & Conditions and Privacy Policy of the external website. Would you like to continue?

PP-UNP-IND-0012 July 2022


​​​​​​​